Jiahao Su^*, Meiqin Cai^*, Wensheng Li^*, Bo Hou^†, Haiyong He^†, Cong Ling^†,Tengchao Huang^†, Huijiao Liu^†, Ying Guo^*

Oncology Research, Vol.24, No.2, pp. 117-128, 2016, DOI:10.3727/096504016X14612603423511

Abstract Glioblastoma (GBM) is the most common primary malignant brain tumor that nearly always results in a bad prognosis. Temozolomide plus radiotherapy (TEM+RAD) is the most common treatment for newly diagnosed GBM. With the development of molecularly targeted drugs, several clinical trials were reported; however, the efficacy of the treatment remains controversial. So we attempted to measure the dose of the molecularly targeted drug that could improve the prognosis of those patients. The appropriate electronic databases (PubMed, MEDLINE, EMBASE, and the Cochrane Library) were searched for relevant studies. A meta-analysis was performed after determining which studies… More >

Xiaoting Wei, Lili Mao, Zhihong Chi, Xinan Sheng, Chuanliang Cui, Yan Kong, Jie Dai, Xuan Wang, Siming Li, Bixia Tang, Bin Lian, Xieqiao Yan, Xue Bai, Li Zhou, Jun Guo, Lu Si

Oncology Research, Vol.27, No.4, pp. 495-501, 2019, DOI:10.3727/096504018X15331163433914

Abstract Melanoma is an aggressive malignancy with a poor prognosis. Current studies show that imatinib treatment is a promising approach in treating advanced melanoma patients harboring c-Kit mutations or amplifications. We retrospectively analyzed the clinical medical records of 78 patients with metastatic melanoma harboring c-Kit mutations or amplifications. These patients were treated with imatinib at a dose of 400 mg/day continuously unless intolerable toxicities or disease progression occurred. Endpoints for exploration included overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and disease of control rate (DCR). The median OS and PFS of all patients were More >

JUNQI GUO^1,2,#, YUN YANG^1,2,#, WEI ZHAO^1,2, ZHONGHAI YAN³, XIA YANG⁴, YUNFEI YAN^1,2, RUIMIN HAO^1,2, JINXIA HU^1,2,*, FEI JIAO^1,2,*

BIOCELL, Vol.45, No.3, pp. 627-638, 2021, DOI:10.32604/biocell.2021.013496

Abstract Increasing evidence indicates that aberrant expressions of some microRNAs are associated with cancer progression. However, the roles and biological mechanisms of miRNA-16-5p in human non-small cell lung cancer (NSCLC) are not to be well studied. Here, we validated that the expression of miR-16-5p was decreased significantly in NSCLC samples and cell lines. The correlation between the clinicopathological features of NSCLC and the miR-16- 5p expression showed that the expression of miR-16-5p in non-small cell lung cancer was linked with the advanced TNM stage, positive lymph node metastasis, with short overall survival (OS). Also, a negative More >